Comment
Author: Admin | 2025-04-28
HomeNamzaricGeneric Availability Last updated on Jan 8, 2025.Namzaric is a brand name of donepezil/memantine, approved by the FDA in the following formulation(s):NAMZARIC (donepezil hydrochloride; memantine hydrochloride - capsule, extended release;oral) Manufacturer: ABBVIE Approval date: December 23, 2014 Strength(s): 10MG;14MG [RLD] [AB], 10MG;28MG [RLD] [AB] Manufacturer: ABBVIE Approval date: July 18, 2016 Strength(s): 10MG;7MG [RLD], 10MG;21MG [RLD] [AB] Has a generic version of Namzaric been approved?A generic version of Namzaric has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Namzaric and have been approved by the FDA:MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE (donepezil hydrochloride; memantine hydrochloride capsule, extended release;oral) Manufacturer: AMNEAL PHARMS Approval date: January 27, 2017 Strength(s): 10MG;14MG [AB], 10MG;28MG [AB] Manufacturer: ANI PHARMS Approval date: December 15, 2023 Strength(s): 10MG;21MG [AB] Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Namzaric. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.See also: Generic Drug FAQ.Related patentsPatents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims. Patent 8,039,009Patent expiration dates: March 24, 2029✓ Patent use: MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE Patent 8039009*PEDPatent expiration dates: September 24, 2029✓ Pediatric exclusivity Patent 8,058,291Patent expiration dates: December 5, 2029✓ Patent use: MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE Method and composition for administering an NMDA receptor antagonist to a subjectPatent 8,168,209Issued: May 1, 2012Inventor(s): Went Gregory T. & Fultz Timothy J. & Porter Seth & Meyerson Laurence R. & Burkoth Timothy S.Assignee(s): Adamas Pharmaceuticals, Inc.The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.Patent expiration dates: November 22, 2025✓ Drug product✓ Sponsor has requested patent be delisted Method and composition for administering an NMDA receptor antagonist to a subjectPatent 8168209*PEDIssued: May 1, 2012Inventor(s): Went Gregory T. & Fultz Timothy J. & Porter Seth & Meyerson Laurence R. & Burkoth Timothy S.Assignee(s): Adamas Pharmaceuticals, Inc.The invention provides methods and compositions for
Add Comment